• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Fostimon
    / Tzamal

    Active Ingredient
    Urofollitropin 75 IU/vial, 150 IU/vial

    Status in Israel

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft


    75 IU

    partial basket chart 14010 6426


    150 IU

    partial basket chart 14011 6427

    Related information


    See prescribing information for full details.


    A treatment with FSH followed by the administration of human chronic gonadotrophin (HCG) is indicated to induce ovulation in infertile women suffering from hypothalamus or hypophyseal disorders and in spanomenorrhoeic or amenorrhoeic women. These women belong to the WHO group II and have generally already been treated with clomiphene citrate. Most have polycystic ovarian syndrome. FSH offers good therapeutic prospects for patients whose LH:FSH ratio has to be adjusted, avoiding an exogenous supply of LH. FSH may be used alone or in concomitance with human menopausal gonadotropin (HMG) in order to stimulate multiple follicular growth in patients involved in medicdbally assisted reproduction programs (IVF-ET, GIFT).


    Pregnancy, lactation. Hypersensitivity to urofollitropin (FSH) or to any other ingredients of this medicdbine; enlarged ovaries or cysts not caused by a hormonal disorder (polycystic ovarian disease); bleeding of unknown cause; cancer of the ovaries, uterus or breast; abnormal swelling (tumor) of the pituitary gland or hypothalamus (brain); early menopause, malformation of the sexual organs or certain tumors of the womb that would make a normal pregnancy impossible.

    Special Precautions

    See prescribing information for full details.

    Side Effects

    See prescribing information for full details.

    Drug interactions

    See prescribing information for full details.

    IBSA Institute Biochimique